SELLAS Life Sciences Group, Inc. — Director's Dealing 2014

Jan 30, 2014

SEC Form 4/A — Form 4/A

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2013-11-26

Reporting Person: Ahn Mark J (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-11-26	Stock Option (right to buy)	$3.88	A	600000	Acquired	2023-11-26	Common Stock (600000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.

F2: The options will vest in equal quarterly installments of 37,500 shares for four years beginning on February 26, 2014 with all such options being fully vested on November 26, 2017.